Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Oakrum Pharma, LLC
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Brand Name : Jadenu
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 22, 2021
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Oakrum Pharma, LLC
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Details : DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders.
Brand Name : DST-0509
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 02, 2021
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?